PDCD1 and melanoma: Indeed, ICIs targeting CTLA-4 and PD-1 have shown clinical activity against HNSCC, advanced melanoma, renal cell carcinoma, non-small-cell lung cancer, Hodgkin’s lymphoma, endometrial cancer, and bladder cancer [167,168].